Chong Kun Dang Holdings: Q1 2026 Operating Profit Surges 62%... Dividend Income and R&D Milestones

Consolidated Q1 2026 operating profit: 19.3B KRW (+62% YoY), net profit attributable to parent: 12.9B KRW (+117%), EPS 2,708 won.
Separate dividend income: 9.6B KRW (+67%) from subsidiaries (e.g., Chong Kun Dang).
Key associate Chong Kun Dang (26.7% stake) sales: 447.8B KRW (+12%), solid performance.
Kyungbo Pharm sales: 66.1B KRW (+9.1%); Chong Kun Dang Bio: 40.7B KRW (-4.3%); Chong Kun Dang Health: 123.8B KRW (-7.8%).
R&D pipeline: CKD-510 (licensed to Novartis, global Phase 2), CKD-703 (ADC Phase 1), biosimilars CKD-704/706 (Phase 1 in Europe).
Financial structure: debt ratio 81.8% (FY2025: 78.4%), net debt ratio 55.5%.
Dividend: FY2025 year-end 1,400 won/share (payout ratio 56%), 22 consecutive years.
Risks: subsidiary Kyungbo Pharm facing embezzlement indictment and drug law violations; choline alfoscerate litigation ongoing.